Chardan Capital Rates SAB Biotherapeutics (SABS) buy

Chardan Capital keeps its buy rating on SAB Biotherapeutics with a $16 price target, a 307.12% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 9:00 AM EDT · Updated Jun 23, 2026, 12:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Chardan Capital rated SAB Biotherapeutics, Inc. ($SABS) "buy" with a $16 price target on June 17, 2026.

Since the rating, $SABS is down 0.5% after 1 week, down 8.3% after 1 month and down 34.5% to date (from the $3.86 close on Jun 17, 2026).

SABS SAB Biotherapeutics, Inc.

$2.53 -32.89% year to date

Daily close · Oct 16, 2026

Key Points

Chardan Capital reiterated its buy rating on SAB Biotherapeutics, Inc. (SABS) with a $16 price target on June 17, 2026.
Chardan Capital's $16 price target implies 307.12% upside from SAB Biotherapeutics, Inc.'s ($SABS) current $3.93 share price.
Shares of SABS traded at $3.66, with a market cap of about $279.9 million and a 52-week range between $1.67 and $6.60.
Institutional investors like Perceptive Advisors LLC increased their holdings significantly, reflecting ongoing interest in the company's potential.

Get $SABS trade alerts by text

We text you when insiders, Congress or big funds trade $SABS. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated SAB Biotherapeutics, Inc. alert may contain errors. Disclosures

Chardan Capital has reiterated its buy rating on SAB Biotherapeutics, Inc. (NasdaqCM: SABS) with a price target of $16. This reaffirmation by analyst Keay Nakae on June 17, 2026, suggests continued confidence in the company's growth prospects. Shares were trading at $3.66 on the same day.

SAB Biotherapeutics, Inc. Stock Up 12.0%

Shares of NasdaqCM:SABS were trading near $3.66. SAB Biotherapeutics has a market cap of approximately $279.9 million and a forward P/E ratio that is not meaningful as the company is not currently profitable. The stock's 52-week range is between $1.67 and $6.60, with a 50-day moving average of $3.68 and a 200-day moving average of $3.49. The company maintains a strong liquidity position with a current ratio of 11.45 and a quick ratio of 11.06, while its debt-to-equity ratio stands at 2.72.

12-month forecast

$SABS price target

SAB Biotherapeutics, Inc. daily closes and this analyst's $16 target. Not advice.

Other Institutional Activity in SAB Biotherapeutics

Perceptive Advisors LLC significantly increased its holdings in SAB Biotherapeutics by 5,628,533 shares, ending with 6,431,743 shares valued at about $24.63 million. Meanwhile, Caligan Partners LP entered a new position with 7,967,207 shares worth approximately $30.51 million. Balyasny Asset Management L.P. also boosted its stake by 3,285,000 shares, now holding 3,760,439 shares valued around $14.40 million. Other funds like Vivo Capital, RA Capital Management, and Commodore Capital maintained their positions without changes.

Insider Buying and Selling at SAB Biotherapeutics, Inc.

Notable insider transactions include Chief Financial Officer Lucy To acquiring 2,400,000 shares on February 3, 2026, and Chief Operating Officer Christoph Lawrence Bausch purchasing 1,800,000 shares on the same date. CEO Samuel Reich also bought 4,800,000 shares on February 3, 2026. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 17, 2026, Chardan Capital maintained its buy rating on SAB Biotherapeutics with a $16 price target. Leerink Partners and HC Wainwright & Co. also maintained buy ratings with targets of $12 and $10, respectively, on June 15. Citigroup initiated coverage with a buy rating and an $11 target on May 22. The consensus among 10 analysts is a strong buy, with an average target price of $10.60.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company based in Miami Beach, Florida. It focuses on developing human polyclonal immunotherapeutic antibodies aimed at treating immune system disorders and infectious diseases. Its key product, SAB-142, is under clinical development for autoimmune type 1 diabetes, currently in Phase 2b trials. Founded in 2014, the company is led by CEO Samuel J. Reich and employs 86 people.

Bottom Line

Chardan Capital's reiteration of its buy rating for SAB Biotherapeutics reflects ongoing optimism about the company's future. With a strong liquidity position and active institutional interest, SAB Biotherapeutics remains a company to watch. Keep in mind that analyst ratings and 13F filings are backward-looking and may not reflect current market conditions.